Windsor skin care products provider Scapa Healthcare says it has completed its acquisition of an England-based maker of wound care products.
Scapa is adding Systagenix and its 335,000-square-foot manufacturing facility in Gargrave, England to its wound care footprint. Financial terms were not disclosed.
Scapa officials said the acquisition, first announced last month, allows them to increase its production and innovation resources.
Scapa has now inked two acquisitions this year.
The Windsor company in March acquired Dallas-based BioMed Laboratories, a maker of over-the-counter pharmaceutical, medical device, wound care and skin care products.
The $19 million deal has a cash consideration up to $13 million, with the final amount depending on performance over the next two years.
